ITERION THERAPEUTICS ANNOUNCES PROMISING PHASE 1B DATA FOR TEGAVIVINT IN COMBINATION WITH OSIMERTINIB IN FIRST-LINE EGFR-MUTATED NON-SMALL CELL LUNG CANCER

Reuters · 1d ago

Please log in to view news